Understanding the serum vitamin B12 level and its implications for treating neuropsychiatric conditions: An orthomolecular perspective

Journal of Orthomolecular Medicine

Volumn 25, Issue 2, 2010, Pages 77-88

  Prousky, Jonathan E ^a  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; HOMOCYSTEINE; HYDROXOCOBALAMIN; MECOBALAMIN; METHYLMALONIC ACID; S ADENOSYLMETHIONINE;

ANTIINFLAMMATORY ACTIVITY; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DEPRESSION; DRUG ACTIVITY; DRUG ERUPTION; FATIGUE; GENE EXPRESSION; HUMAN; HYPERSOMNIA; INBORN ERROR OF METABOLISM; MENTAL DISEASE; METHYLATION; PARANOID SCHIZOPHRENIA; PUERPERAL DEPRESSION; REVIEW; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL;

EID: 77954852298     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 12 deficiency. Am Fam Physician, 2003; 67: 979-986, 993-994.
2. 12 (cobalamin) deficiency in elderly patients. CMAJ, 2004; 171: 251-259.
3. Becker M, Axelrod DJ, Oyesanmi O, et al: Hematologic problems in psychosomatic medicine. Psychiatr Clin North Am, 2007; 30: 739-759.
4. 12 in the treatment of tiredness. Br J Nutr, 1973; 30: 277-283.
5. 12 levels of cerebrospinal fluid in patients with organic mental disorders. J Orthomolec Psych, 1983; 12: 305-311. (Pubitemid 14186207)
6. 12 status in CSF. Am J Psychiatry, 1984; 141: 136-137.
7. 12 treatment-preliminary study. Jpn J Psychiatry Neurol, 1988;42:65-71.
8. 12: placebo or neglected therapeutic tool. Med Hypotheses, 1989; 28: 155-165.
9. 12). Sleep, 1991; 14: 414-418.
10. 12): a case report. Psychiatry Clin Neurosci, 1995; 49(5-6): 305-307.
11. 12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiatry, 2003; 3: 17. (Pubitemid 38729338)
12. 12 study. Age Ageing, 2006; 35: 416-422. (Pubitemid 43941812)
13. 12 status and rate of brain volume loss in community-dwelling elderly. Neurology, 2008; 71: 826-832.
14. Karakula H, Opolska A, Kowal A, et al: Does diet affect mood? The significance of folic acid and homocysteine. Pol Merkur Lekarski, 2009; 26: 136-141.
15. Hutto BR: Folate and cobalamin in psychiatric illness. Compr Psychiatry, 1997; 38: 305-314.
16. Ho PI, Collins SC, Dhitavat S, et al: Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem, 2001; 78: 249-253. (Pubitemid 32664406)
17. Ho PI, Ortiz D, Rogers E, et al: Multiple aspects of homocysteine neurotoxicity: glutamate excito-toxicity, kinase hyperactivation and DNA damage. J Neurosci Res, 2002; 70: 694-702. (Pubitemid 35397143)
18. Bisschops RH, van der Graaf Y, Mali WP, et al: Elevated levels of plasma homocysteine are associated with neurotoxicity. Atherosclerosis, 2004; 174: 87-92.
19. Zieminska E, Matyja E, Kozlowska H, et al: Excitotoxic neuronal injury in acute homocysteine neurotoxicity: role of calcium and mitochondrial alterations. Neurochem Int, 2006; 48(6-7): 491-497.
20. Kaplan BJ, Crawford SG, Field CJ, et al: Vitamins, minerals, and mood. Psychol Bull, 2007; 133: 747-760.
21. Pauling L: Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science, 160: 265-271.
22. Ames BN, Elson-Schwab I, Silver EA: High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding (increased Km): relevance to genetic diseases and polymorphisms. Am J Clin Nutr, 2002; 75: 616-658.
23. Regland B, Johansson BV, Gottfries CG: Homocysteinemia and schizophrenia as a case of methylation deficiency. J Neural Transm Gen Sect, 1994; 98: 143-152.
24. Regland B, Johansson BV, Grenfeldt B, et al: Homocysteinemia is a common feature of schizophrenia. J Neural Transm Gen Sect, 1995; 100: 165-169.
25. 12 availability and increased risk of frailty. J Nutr Health Aging, 2010; 14: 73-77.
26. Heaney RP: Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr, 2003; 78: 912-919.
27. 12? Nutr Rev, 2002; 60: 142-151.
28. 12) on in vitro cytokine production of peripheral blood mono-nuclear cells. J Clin Lab Immunol, 1992; 37: 173-182.
29. 12 deficiency. Ann Intern Med, 1987; 106: 707-710.
30. 12) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry. Am J Med, 1993; 94: 589-594.
31. 12 status on a mostly raw vegan diet with follow-up using tablets, nutritional yeast, or probiotic supplements. Ann Nutr Metab, 2000; 44: 229-234.
32. 12? Can Fam Physician, 1997; 43: 917-922.
33. Ikeda T, Yamamoto K, Takahashi K, et al: Treatment of Alzheimer-type dementia with intravenous mecobalamin. Clin Ther, 1992; 14: 426-437.
34. McCaddon A, Hudson PR: L-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline. CNS Spectr, 2010;15(1 Suppl 1): 2-5; discussion 6.
35. [No authors listed]. Methylcobalamin. Altern Med Rev, 1998; 3: 461-463.
36. 12 therapy in Japanese patients with multiple sclerosis. Intern Med, 1994; 33: 82-86.
37. 12 body stores during oral and parenteral treatment of pernicious anemia. Acta Med Scand, 1978; 204: 81-84.
38. 12. Int Clin Nut Rev, 1989; 9: 64-65.
39. Werbach MR, Moss J: Acne vulgaris. Textbook of Nutritional Medicine. Tarzana, CA. Third Line Press, Inc. 1999; 67-70.